Voyager Acquisition Corp. (VACH)
Automate Your Wheel Strategy on VACH
With Tiblio's Option Bot, you can configure your own wheel strategy including VACH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VACH
- Rev/Share 0.0
- Book/Share 9.8878
- PB -22.6023
- Debt/Equity 0.0
- CurrentRatio 5.8145
- ROIC -0.0035
- MktCap 328583729.0
- FreeCF/Share -0.0366
- PFCF -354.7421
- PE 39.6687
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0551
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.
Read More
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025.
Read More
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors
Read More
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors
Read More
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies
Read More
About Voyager Acquisition Corp. (VACH)
- IPO Date 2024-09-30
- Website https://www.voyageracq.com
- Industry Shell Companies
- CEO Adeel Rouf Ennis
- Employees None